Study to Evaluate KOS-1584 in Patients With Advanced or Metastatic Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

Bristol-Myers Squibb (BMS)

Status and phase: Completed; Phase 2

Conditions: Non-Small Cell Lung Cancer

Treatments: Drug: KOS-1584

Study type: Interventional

Funder types: Industry

Identifiers

NCT00651508

CA202-002

KOS-1584-203

Details and patient eligibility

About

The purpose of this study is to determine the Objective Response Rate of KOS-1584, as a single agent in patients with stage IIIB/IV NSCLC whose disease has progressed following initial chemotherapy.

Enrollment: 1 patient

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Histologically or cytologically proven NSCLC, Stage IIIB or Stage IV.
• Eligible patients must have received only one prior chemotherapy regime for Stage IIIB/IV NSCLC.
• Good performance status.

Exclusion criteria

• Prior treatment with an epothilone.
• Known central nervous system (CNS) metastases.
• Any chemotherapy, radiation therapy or immunotherapy or any investigational agent (therapeutic or diagnostic) within 3 weeks prior to first study drug administration.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

1 participants in 1 patient group

Single Arm 25mg/m2

Experimental group

Description:

KOS-1584 25mg/m2

Treatment:

Drug: KOS-1584